SCHEMBL5401499

SCHEMBL5401499

COc1ccc(-c2cnc(N)nc2-c2c[nH]c(C(=O)N3CCN(c4ccccn4)CC3)c2)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.51
ALDH1A1 P00352 8/20 0.49
KDM4E B2RXH2 6/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP1A2 P05177 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TLR7 Q9NYK1 2/20 0.48
HSD17B10 Q99714 5/20 0.47
HPGD P15428 2/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47
TSHR P16473 2/20 0.47
CCKAR P32238 1/20 0.47
LMNA P02545 1/20 0.47
ALOX15 P16050 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TLR9 Q9NR96 1/20 0.46
TLR8 Q9NR97 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5415801 0.88 ALDH1A1 (0.53) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL5405421 0.87 ADORA1 (0.53) ADORA1KMT2ATLR7CCKARNPSR1
SCHEMBL5405217 0.87 ADORA1 (0.50) ADORA1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5402200 0.85 KMT2A (0.53) ADORA1ALDH1A1KDM4ECYP2C9CYP2C19
SCHEMBL5405504 0.84 PRKCZ (0.55) ADORA1MEN1KMT2AHPGDCCKAR
SCHEMBL5404432 0.84 ADORA1 (0.52) ADORA1TLR7TSHRCCKARNPSR1
SCHEMBL5400730 0.84 ADORA1 (0.49) ADORA1KMT2ATLR7CCKARTLR9
SCHEMBL27582134 0.83 ADORA1 (0.48) ADORA1ALDH1A1KDM4EKMT2ATLR7
SCHEMBL5404667 0.83 ADORA1 (0.52) ADORA1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL27582136 0.82 ADORA1 (0.47) ADORA1ALDH1A1KDM4EKMT2ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-6743791-B2 ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS VERTEX PHARMACEUTICALS INCORPORATED 2004-06-01 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 ADORA1 4421/4885ALDH1A1 3899/4885KDM4E 4090/4885
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885ALDH1A1 2909/4885KDM4E 3549/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885ALDH1A1 2909/4885KDM4E 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.